Skip to main content
. 2017 Jun 1;14(2):1505–1511. doi: 10.3892/ol.2017.6295

Table I.

Comparison of the patient background between the DPD-positive and DPD-negative groups.

Characteristic Patients exhibiting positive DPD expression (n=34) Patients exhibiting negative DPD expression (n=32) P-value
Median age, years (range) 71 (50–80) 66 (51–81) 0.266
Sex 0.025
  Male 23 (67.6%) 13 (40.6%)
  Female 11 (32.4%) 19 (59.4%)
Surgical procedure 0.235
  PD 24 (70.6%) 16 (50.0%)
  DP 8 (23.5%) 11 (34.4%)
  TP 2 (5.9%) 5 (15.6%)
  Median size of tumor, mm (range) 34.5 (18–105) 40 (15–80) 0.718
Pathological type 0.708
  tub1 20 (58.8%) 19 (59.4%)
  tub2 10 (29.4%) 8 (25.0%)
  por 3 (8.8%) 2 (6.3%)
  Others 1 (2.9%) 3 (9.4%)
Pathological T factor 0.163
  T2 1 (2.9%) 0 (0.0%)
  T3 32 (94.1%) 32 (100.0%)
  T4 1 (2.9%) 0 (0.0%)
Pathological N factor 0.351
  N0 11 (32.4%) 6 (18.8%)
  N1 23 (67.6%) 26 (81.3%)
Stage (7th UICC classification) 0.351
  IIA 11 (32.4) 6 (18.8)
  IIB 22 (64.7%) 26 (81.3%)
  III 1 (2.9%) 0 (0.0%)

DPD, dihydropyrimidine dehydrogenase; PD, pancreaticoduodenectomy; DP, distal pancreatectomy; TP, total pancreatectomy; tub1, well-differentiated tubular adenocarcinoma; tub2, moderately differentiated tubular adenocarcinoma; por, poorly differentiated adenocarcinoma; T, tumor; N, node; UICC, Union for International Cancer Control.